Publication

This paper first tackles the question concerning who owns and controls pathogen materials from the standpoint of developing effective preventatives and treatments and assuring their supply. It then turns to the question of the most appropriate forum for negotiating the terms and conditions of access to pathogen materials, including questions regarding Intellectual property rights (IPR) protection. Finally, the paper examines some issues connected with the sharing of benefits from use of such resources.